[Congressional Record Volume 155, Number 111 (Wednesday, July 22, 2009)]
[Senate]
[Pages S7884-S7887]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

      By Mr. REID (for Ms. Mikulski (for herself, Mr. Bond, Mrs. 
        Gillibrand, Mr. Menendez, Mr. Burr, and Ms. Collins)):
  S. 1492. A bill to amend the Public Health Service Act to fund 
breakthroughs in Alzheimer's disease research while providing more help 
to caregivers and increasing public education about prevention; to the 
Committee on Health, Education, Labor, and Pensions.
  Ms. MIKULSKI. Mr. President, today, I rise to introduce the 
Alzheimer's Breakthrough Act of 2009. This critical bipartisan 
legislation passed the HELP Committee in 2007, but it has yet to pass 
the Senate. My hope is that we can finish the job this year and finally 
get this legislation signed into law.
  Alzheimer's' disease is an alarming and mounting crisis that we must 
address. Today there are over five million Americans living with 
Alzheimer's disease. That number is expected to triple by 2050 in a 
nation where ten million Americans care for a sick family member.
  We know a lot about Alzheimer's disease but it's been 100 years since 
it was first diagnosed, and we still have no cure or proven ways to 
prevent the disease. Urgency is needed in developing better treatments 
and better assistance for families impacted by the disease as the baby 
boom generation ages. If nothing is done, Alzheimer's will cost 
Medicare and Medicaid $19.89 trillion between 2010 and 2050.
  The Alzheimer's Breakthrough Act of 2009 responds to this crisis in 
four ways.
  First, it doubles funding for Alzheimer's research at NIH to $2 
billion for fiscal year 2010, making Alzheimer's research a priority. 
Through this commitment, the bill gives researchers adequate resources 
to make breakthroughs in diagnosis, prevention and intervention, 
bringing us closer to a cure.
  Second, the bill creates the National Summit on Alzheimer's. This 
Summit will bring together the Nation's best researchers, policymakers 
and public health professionals to discuss the most promising 
breakthroughs for saving lives and livelihood, and to generate 
priorities in moving forward in the fight against Alzheimer's.
  Third, the act enhances public health activities related to 
Alzheimer's through the CDC's ``Roadmap to Maintaining Cognitive 
Health.''

[[Page S7885]]

  Finally, the Alzheimer's Breakthrough Act provides family and 
caregiver support by expanding the Alzheimer's 24/7 call center, which 
provides crisis assistance and referrals to local community programs. 
The bill also expands the multilingual capacity of the call center.
  America needs this legislation. Alzheimer's takes a toll on many 
victims. The disease is awful for the person living with it, 
emotionally and financially draining for caregivers and it is now 
costing the nation $175 billion annually, a number that could rise to 
$1 trillion annually by 2050.
  We know the family of an Alzheimer's patient suffers gravely. The 
out-of-pocket cost of caring for an aging parent or spouse averages 
about $5,500 a year for necessities like groceries, household goods and 
drugs and medical copayments. If the care is long-distance, the cost 
could be up to $8,700 a year. Caregivers spend ten percent of their 
household income caring for a sick loved one who is suffering from this 
terrible disease.
  Experts have told us ``we will lose opportunities if we don't move 
quickly'' and that ``we are at a crucial point where NIH funding can 
make a difference.'' We know about the long goodbye. Alzheimer's is a 
disease that affects millions of Americans including our All-American 
President Ronald Reagan and his beloved caregiver, First Lady Nancy 
Reagan. Now we need a response supported by millions that will lead to 
breakthroughs and ensure we are assisting patients and their families 
dealing with this disease on a daily basis.
  Passage of the Alzheimer's Breakthrough Act of 2009 will help us 
advance the study and treatment of Alzheimer's to make a difference in 
the lives of millions of Americans and to equip caregivers with the 
resources and support services they need to care for their loved ones. 
This legislation is critical to the American public and America's 
future. We must act now.
  Mr. President, I ask unanimous consent that the text of the bill be 
printed in the Record.
  There being no objection, the text of the bill was ordered to be 
printed in the Record, as follows:

                                S. 1492

       Be it enacted by the Senate and House of Representatives of 
     the United States of America in Congress assembled,

     SECTION 1. SHORT TITLE.

       This Act may be cited as the ``Alzheimer's Breakthrough Act 
     of 2009''.

     SEC. 2. FINDINGS.

       Congress makes the following findings:
       (1) Alzheimer's disease is a disorder that destroys cells 
     in the brain. The disease is the leading cause of dementia, a 
     condition that involves gradual memory loss, decline in the 
     ability to perform routine tasks, disorientation, difficulty 
     in learning, loss of language skills, impairment of judgment, 
     and personality changes. As the disease progresses, people 
     with Alzheimer's disease become unable to care for 
     themselves. The loss of brain cells eventually leads to the 
     failure of other systems in the body.
       (2) An estimated 5,300,000 Americans have Alzheimer's 
     disease and 1 in 10 individuals has a family member with the 
     disease. By 2050, the number of individuals with the disease 
     could reach 16,000,000 unless science finds a way to prevent 
     or cure the disease.
       (3) One in 8 people over the age of 65, and nearly half of 
     those over the age of 85 have Alzheimer's disease. Younger 
     people also get the disease.
       (4) The Alzheimer's disease process may begin in the brain 
     as many as 20 years before the symptoms of Alzheimer's 
     disease appear. An individual will live an average of 4 to 6 
     years, and as many as 20 years, once the symptoms of 
     Alzheimer's disease appear.
       (5) In 2005, Medicare alone spent $91,000,000,000 for the 
     care of individuals with Alzheimer's disease and this amount 
     is projected to increase to $160,000,000,000 in 2010.
       (6) Ninety-five percent of Medicare beneficiaries with 
     Alzheimer's disease have one or more other chronic conditions 
     that are common in the elderly, such as coronary heart 
     disease (26 percent), congestive heart failure (16 percent), 
     diabetes (23 percent), and chronic obstructive pulmonary 
     disease (15 percent).
       (7) Seven in 10 individuals with Alzheimer's disease live 
     at home. Cost for care at home is higher for people with 
     Alzheimer's disease than other individuals. Almost all 
     families pay some out-of-pocket costs.
       (8) Half of all nursing home residents have Alzheimer's 
     disease or a related disorder. The average annual cost of 
     Alzheimer's disease nursing home care is more than $77,000. 
     Medicaid pays half of the total nursing home bill and helps 2 
     out of 3 residents pay for their care. Medicaid expenditures 
     for nursing home care for people with Alzheimer's disease are 
     estimated to increase from $21,000,000,000 in 2005 to 
     $24,000,000,000 in 2010.
       (9) In fiscal year 2007, the Federal Government spent an 
     estimated $411,000,000 on Alzheimer's disease research. Over 
     the next 40 years, Alzheimer's disease-related costs to 
     Medicare and Medicaid alone are projected to total 
     $20,000,000,000,000 in constant dollars, rising to over 
     $1,000,000,000,000 per year by 2050. This amounts to less 
     than a penny spent on Alzheimer's disease research for each 
     dollar that the Federal Government spends on Alzheimer's 
     disease-related costs each year.
       (10) It is estimated that the annual value of the informal 
     care system is $94,000,000,000. Family caregiving comes at 
     enormous physical, emotional, and financial sacrifice, 
     putting the whole system at risk.
       (11) Almost 60 percent of caregivers of individuals with 
     Alzheimer's disease are women, and over one-fourth have 
     children or grandchildren under the age of 18 living at home. 
     Caregiving leaves them less time for other family members and 
     they are much more likely to report family conflicts because 
     of their caregiving role.
       (12) Most Alzheimer's disease caregivers work outside the 
     home before beginning their caregiving careers, but 
     caregiving forces them to miss work, cut back to part-time, 
     take less demanding jobs, choose early retirement, or give up 
     work altogether. As a result, in 2002, Alzheimer's disease 
     cost American business an estimated $36,500,000,000 in lost 
     productivity, as well as an additional $24,600,000,000 in 
     business contributions to the total cost of care.

   TITLE I--INCREASING THE FEDERAL COMMITMENT TO ALZHEIMER'S RESEARCH

     SEC. 101. DOUBLING NIH FUNDING FOR ALZHEIMER'S DISEASE 
                   RESEARCH.

       For the purpose of conducting and supporting research on 
     Alzheimer's disease (including related activities under 
     subpart 5 of part C of title IV of the Public Health Service 
     Act (42 U.S.C. 285e et seq.)), there are authorized to be 
     appropriated $2,000,000,000 for fiscal year 2010, and such 
     sums as may be necessary for each of fiscal years 2011 
     through 2014.

     SEC. 102. PRIORITY TO ALZHEIMER'S DISEASE RESEARCH.

       Section 443 of the Public Health Service Act (42 U.S.C. 
     285e) is amended--
       (1) by striking ``The general'' and inserting the 
     following:
       ``(a) In General.--The general;'' and
       (2) by adding at the end the following:
       ``(b) Priorities.--The Director of the Institute shall, in 
     expending amounts appropriated to carry out this subpart, 
     give priority to conducting and supporting Alzheimer's 
     disease research.''.

     SEC. 103. ALZHEIMER'S DISEASE PREVENTION INITIATIVE.

       Section 443 of the Public Health Service Act (42 U.S.C. 
     285e), as amended by section 102, is further amended by 
     adding at the end the following:
       ``(c) Prevention Trials.--The Director of the Institute 
     shall increase the emphasis on the need to conduct 
     Alzheimer's disease prevention trials within the National 
     Institutes of Health.
       ``(d) Neuroscience Initiative.--The Director of the 
     Institute shall ensure that Alzheimer's disease is maintained 
     as a high priority for the neuroscience initiative of the 
     National Institutes of Health.''.

     SEC. 104. ALZHEIMER'S DISEASE CLINICAL RESEARCH.

       (a) Clinical Research.--Subpart 5 of part C of title IV of 
     the Public Health Service Act (42 U.S.C. 285e et seq.) is 
     amended by adding at the end the following:

     ``SEC. 445J. ALZHEIMER'S DISEASE CLINICAL RESEARCH.

       ``(a) In General.--The Director of the Institute, pursuant 
     to section 444(d), shall conduct and support cooperative 
     clinical research regarding Alzheimer's disease. Such 
     research shall include--
       ``(1) investigating therapies, interventions, and agents to 
     detect, treat, slow the progression of, or prevent 
     Alzheimer's disease;
       ``(2) enhancing the national infrastructure for the conduct 
     of clinical trials on Alzheimer's disease;
       ``(3) developing and testing novel approaches to the design 
     and analysis of such trials;
       ``(4) facilitating the enrollment of patients for such 
     trials, including patients from diverse populations;
       ``(5) developing improved diagnostics and means of patient 
     assessment for Alzheimer's disease;
       ``(6) the conduct of clinical trials on potential 
     therapies, including readily available compounds such as 
     herbal remedies and other alternative treatments;
       ``(7) research to develop better methods of early 
     diagnosis, including the use of current imaging techniques; 
     and
       ``(8) other research, as determined appropriate by the 
     Director of the Institute after consultation with the 
     Alzheimer's disease centers and Alzheimer's disease research 
     centers established under section 445.
       ``(b) Early Diagnosis and Detection Research.--
       ``(1) In general.--The Director of the Institute, in 
     consultation with the directors of other relevant institutes 
     and centers of the National Institutes of Health, shall 
     conduct, or make grants for the conduct of, research related 
     to the early detection, diagnosis, and prevention of 
     Alzheimer's disease and of mild cognitive impairment or other 
     potential precursors to Alzheimer's disease.
       ``(2) Evaluation.--The research described in paragraph (1) 
     may include the evaluation of diagnostic tests and imaging 
     techniques.

[[Page S7886]]

       ``(3) Study.--Not later than 1 year after the date of 
     enactment of this section, the Director of the Institute, in 
     cooperation with the heads of other relevant Federal 
     agencies, shall conduct a study, and submit to Congress a 
     report, to estimate the number of individuals with early-
     onset Alzheimer's disease (those diagnosed before the age of 
     65) and related dementias in the United States, the causes of 
     early-onset dementia, and the unique problems faced by such 
     individuals, including problems accessing government 
     services.
       ``(c) Vascular Disease.--The Director of the Institute, in 
     consultation with the directors of other relevant institutes 
     and centers of the National Institutes of Health, shall 
     conduct, or make grants for the conduct of, research related 
     to the relationship of vascular disease and Alzheimer's 
     disease, including clinical trials to determine whether drugs 
     developed to prevent cerebrovascular disease can prevent the 
     onset or progression of Alzheimer's disease.
       ``(d) Treatments and Prevention.--The Director of the 
     Institute shall place special emphasis on expediting the 
     translation of research findings under this section into 
     effective treatments and prevention strategies for 
     individuals at risk of Alzheimer's disease and other 
     dementias.
       ``(e) National Alzheimer's Coordinating Center.--The 
     Director of the Institute may establish a National 
     Alzheimer's Coordinating Center to facilitate collaborative 
     research among the Alzheimer's Disease Centers and 
     Alzheimer's Disease Research Centers established under 
     section 445.''.
       (b) Alzheimer's Disease Centers.--Section 445(a)(1) of the 
     Public Health Service Act (42 U.S.C. 285e-2(a)(1)) is amended 
     by inserting ``, outcome measures, and disease management,'' 
     after ``treatment methods''.

     SEC. 105. RESEARCH ON ALZHEIMER'S DISEASE CAREGIVING.

       Section 445C of the Public Health Service Act (42 U.S.C. 
     285e-5) is amended--
       (1) by striking ``Sec. 445C. Research Program and Plan 
     (a)'' and inserting the following:

     ``SEC. 445C. RESEARCH ON ALZHEIMER'S DISEASE SERVICES AND 
                   CAREGIVING.

       ``(a) Services Research.--'';
       (2) by striking subsections (b), (c), and (e);
       (3) by inserting after subsection (a) the following:
       ``(b) Interventions Research.--The Director of the 
     Institute shall, in collaboration with the directors of the 
     other relevant institutes and centers of the National 
     Institutes of Health, conduct, or make grants for the conduct 
     of, clinical, social, and behavioral research related to 
     interventions designed to help caregivers of patients with 
     Alzheimer's disease and other dementias and improve patient 
     outcomes.'';
       (4) by redesignating subsection (d) as subsection (c); and
       (5) in subsection (c) (as redesignated by paragraph (4)), 
     by striking ``the Director'' and inserting ``Model Curricula 
     and Techniques.--The Director''.

     SEC. 106. NATIONAL SUMMIT ON ALZHEIMER'S DISEASE.

       (a) In General.--Not later than 3 years after the date of 
     enactment of this Act, and every 3 years thereafter, the 
     Secretary of Health and Human Services (referred to in this 
     section as the ``Secretary'') shall convene a National Summit 
     on Alzheimer's Disease to--
       (1) provide a detailed overview of current research 
     activities relating to Alzheimer's disease at the National 
     Institutes of Health; and
       (2) discuss and solicit input related to potential areas of 
     collaboration between the National Institutes of Health and 
     other Federal health agencies, including the Centers for 
     Disease Control and Prevention, the Administration on Aging, 
     the Agency for Healthcare Research and Quality, and the 
     Health Resources and Services Administration, related to 
     research, prevention, and treatment of Alzheimer's disease.
       (b) Participants.--The summit convened under subsection (a) 
     shall include researchers, representatives of academic 
     institutions, Federal and State policymakers, public health 
     professionals, and representatives of voluntary health 
     agencies as participants.
       (c) Focus Areas.--The summit convened under subsection (a) 
     shall focus on--
       (1) a broad range of Alzheimer's disease research 
     activities relating to biomedical research, prevention 
     research, and caregiving issues;
       (2) clinical research for the development and evaluation of 
     new treatments for Alzheimer's disease;
       (3) translational research on evidence-based and cost-
     effective best practices in the treatment and prevention of 
     Alzheimer's disease;
       (4) information and education programs for health care 
     professionals and the public relating to Alzheimer's disease;
       (5) priorities among the programs and activities of the 
     various Federal agencies regarding Alzheimer's disease and 
     other dementias; and
       (6) challenges and opportunities for scientists, 
     clinicians, patients, and voluntary organizations relating to 
     Alzheimer's disease.
       (d) Report.--Not later than 180 days after the date on 
     which the summit is convened under subsection (a), the 
     Director of the National Institutes of Health shall prepare 
     and submit to the appropriate committees of Congress a report 
     that includes a summary of the proceedings of the summit and 
     a description of Alzheimer's disease research, education, and 
     other activities that are conducted or supported through the 
     National Institutes of Health.
       (e) Public Information.--The Secretary shall make readily 
     available to the public information about the research, 
     education, and other activities relating to Alzheimer's 
     disease and other related dementias, that are conducted or 
     supported by the National Institutes of Health.

TITLE II--PUBLIC HEALTH PROMOTION AND PREVENTION OF ALZHEIMER'S DISEASE

     SEC. 201. ENHANCING PUBLIC HEALTH ACTIVITIES RELATED TO 
                   COGNITIVE HEALTH, ALZHEIMER'S DISEASE, AND 
                   OTHER DEMENTIAS.

       Part P of title III of the Public Health Service Act (42 
     U.S.C. 280g et seq.) is amended--
       (1) by redesignating the second and third sections 399R as 
     sections 399S and 399T, respectively; and
       (2) by adding at the end the following:

     ``SEC. 399U. ALZHEIMER'S DISEASE PUBLIC EDUCATION CAMPAIGN.

       ``(a) In General.--The Secretary, acting through the 
     Director of the Centers for Disease Control and Prevention, 
     shall directly or through grants, cooperative agreements, or 
     contracts to eligible entities--
       ``(1) conduct, support, and promote the coordination of 
     research, investigations, demonstrations, training, and 
     studies relating to the control, prevention, and surveillance 
     of the risk factors associated with cognitive health, 
     Alzheimer's disease, and other dementias; and
       ``(2) seek early recognition of, and early intervention in 
     the course of, Alzheimer's disease and other dementias.
       ``(b) Certain Activities.--Activities under subsection (a) 
     shall include--
       ``(1) providing support for the dissemination and 
     implementation of the Roadmap to Maintaining Cognitive Health 
     of the Centers for Disease Control and Prevention to 
     effectively mobilize the public health community into action;
       ``(2) the development of coordinated public education 
     programs, services, and demonstrations which are designed to 
     increase general awareness of cognitive function and promote 
     a brain healthy lifestyle;
       ``(3) the development of targeted communication strategies 
     and tools to educate health professionals and service 
     providers about the early recognition, diagnosis, care, and 
     management of Alzheimer's disease and other dementias, and to 
     provide consumers with information about interventions, 
     products, and services that promote cognitive health and 
     assist consumers in maintaining current understanding about 
     cognitive health based on the best science available; and
       ``(4) providing support for the collection, publication, 
     and analysis of data and the prevalence and incidence of 
     cognitive health, Alzheimer's disease, and other dementias, 
     and the evaluation of existing population-based surveillance 
     systems (such as the Behavioral Risk Factors Surveillance 
     Survey (BRFSS) and the National Health Interview Survey 
     (NHIS)) to identify limitations that exist in the area of 
     cognitive health, and if necessary, the development of a 
     surveillance system for cognitive decline, including 
     Alzheimer's disease and other dementias.
       ``(c) Grants.--The Secretary may award grants under this 
     section--
       ``(1) to State and local health agencies for the purpose 
     of--
       ``(A) coordinating activities related to cognitive health, 
     Alzheimer's disease, and other dementias with existing State-
     based health programs and community-based organizations;
       ``(B) providing Alzheimer's disease education and training 
     opportunities and programs for health professionals; and
       ``(C) developing, testing, evaluating, and replicating 
     effective Alzheimer's disease intervention programs to 
     maintain or improve cognitive health; and
       ``(2) to nonprofit private health organizations with 
     expertise in providing care and services to individuals with 
     Alzheimer's disease for the purpose of--
       ``(A) disseminating information to the public;
       ``(B) testing model intervention programs to improve 
     cognitive health; and
       ``(C) coordinating existing services related to cognitive 
     health, Alzheimer's disease, and other dementias with State-
     based health programs.
       ``(d) Authorization of Appropriations.--For the purpose of 
     carrying out this section, there are authorized to be 
     appropriated $15,000,000 for fiscal year 2010, and such sums 
     as may be necessary for each of fiscal years 2011 through 
     2014.''.

                  TITLE III--ASSISTANCE FOR CAREGIVERS

     SEC. 301. ALZHEIMER'S CALL CENTER.

       Part P of title III of the Public Health Service Act (42 
     U.S.C. 280g et seq.), as amended by section 201, is further 
     amended by adding at the end the following:

     ``SEC. 399V. ALZHEIMER'S CALL CENTER.

       ``(a) In General.--The Secretary, acting through the 
     Administration on Aging, shall award a cooperative grant to a 
     non-profit or community-based organization to support the 
     establishment and operation of an Alzheimer's Call Center 
     that is accessible 24 hours a day, 7 days a week, at the 
     national and local levels, to provide expert advice,

[[Page S7887]]

     care consultation, information, and referrals regarding 
     Alzheimer's disease.
       ``(b) Activities.--The Alzheimer's Call Center established 
     under subsection (a) shall--
       ``(1) collaborate with the Administration on Aging in the 
     development, modification, and execution of the Call Center's 
     work plan;
       ``(2) assist the Administration on Aging in developing and 
     sustaining collaborations between the Call Center, the 
     Eldercare Locator of the Administration of Aging, and the 
     grantees under the Alzheimer's disease demonstration program 
     under subpart II of part K;
       ``(3) provide a 24 hours a day, 7 days a week toll-free 
     call center with trained professional staff who are available 
     to provide care consultation and crisis intervention to 
     individuals with Alzheimer's disease and other dementias, 
     their family and informal caregivers, and others as 
     appropriate;
       ``(4) be accessible by telephone through a single toll-free 
     telephone number, website, and e-mail address; and
       ``(5) evaluate the impact of the Call Center's activities 
     and services.
       ``(c) Multilingual Capacity.--The Call Center established 
     under this section shall have a multilingual capacity and 
     shall respond to inquiries in at least 140 languages through 
     its own bilingual staff and with the use of a language 
     translation service.
       ``(d) Response to Emergency and Ongoing Needs.--The Call 
     Center established under this section shall collaborate with 
     community-based organizations, including non-profit agencies 
     and organizations, to ensure local, on-the-ground capacity to 
     respond to emergency and on-going needs of individuals with 
     Alzheimer's disease and other dementias, their families, and 
     informal caregivers.
       ``(e) Authorization of Appropriations.--For the purpose of 
     carrying out this section, there are authorized to be 
     appropriated $1,000,000 for fiscal year 2010, and such sums 
     as may be necessary for each of fiscal years 2011 through 
     2014.''.

     SEC. 302. INNOVATIVE ALZHEIMER'S CARE STATE MATCHING GRANT 
                   PROGRAM.

       (a) Authorization of Appropriations.--Section 398B(e) of 
     the Public Health Service Act (42 U.S.C. 280c-5(e)) is 
     amended--
       (1) by striking ``and such'' and inserting ``such''; and
       (2) by inserting before the period the following: ``, 
     $25,000,000 for fiscal year 2010, and such sums as may be 
     necessary for each of fiscal years 2011 through 2014''.
       (b) Program Expansion.--Section 398(a) of the Public Health 
     Service Act (42 U.S.C. 280c-3(a)) is amended--
       (1) in paragraph (2), by inserting after ``other respite 
     care'' the following: ``and care consultation, including 
     assessment of needs, assistance with planning and problem 
     solving, and providing supportive listening,'';
       (2) in paragraph (3), by striking ``; and'' and inserting 
     the following: ``, and individuals in frontier areas (in this 
     subsection, defined as areas with 6 or fewer people per 
     square mile or areas in which residents must travel at least 
     60 minutes or 60 miles to receive health care services);'';
       (3) in paragraph (4), by striking the period at the end and 
     inserting a semicolon; and
       (4) by adding at the end the following:
       ``(5) to encourage grantees under this section to 
     coordinate activities with other State officials 
     administering efforts to promote long-term care options that 
     enable older individuals to receive long-term care in home- 
     and community-based settings, in a manner responsive to the 
     needs and preferences of older individuals and their family 
     caregivers;
       ``(6) to encourage grantees under this section to--
       ``(A) engage in activities that support early detection and 
     diagnosis of Alzheimer's disease and other dementias;
       ``(B) provide training about how Alzheimer's disease can 
     affect behavior and impede communication in medical and 
     community settings to--
       ``(i) medical personnel, including hospital staff, 
     emergency room personnel, home health care workers and 
     physician office staff;
       ``(ii) rehabilitation services providers; and
       ``(iii) caregivers of individuals with Alzheimer's disease;
       ``(C) develop guidelines to provide the medical community 
     with up-to-date information about the best methods of care 
     for individuals with Alzheimer's disease;
       ``(D) inform community physicians about available resources 
     to assist the physician in detecting and managing Alzheimer's 
     disease; and
       ``(E) raise awareness among community physicians about the 
     availability of community-based organizations which can 
     assist individuals with Alzheimer's disease and their 
     caregivers;
       ``(7) to encourage grantees under this section to engage in 
     activities that use findings from evidence-based research on 
     service models and techniques to support individuals with 
     Alzheimer's disease and their caregivers; and
       ``(8) to encourage grantees under this section to 
     incorporate best practices for effectively serving 
     individuals with Alzheimer's disease in community-based 
     settings into systems initiatives and long-term care 
     activities.''.
                                 ______